Amgen Czech Republic made a net profit of CZK 35.8 mil under revenues of CZK 604 mil in 2015, down -11.4% and -5.06%, respectively, when compared to the last year. This translates into a net margin of 5.93%.
Historically, the firm’s net profit reached an all time high of CZK 46.2 mil in 2011 and an all time low of CZK 5.00 mil in 2005. Since 2010, the firm's net profit has increased 21.9% or 4.05% a year on average.
On the operating level, EBITDA reached CZK 46.3 mil, up -15.0% when compared to the previous year. Over the last five years, company's EBITDA has grown 3.62% a year on average.
As far as Amgen Czech Republic's peers are concerned, Roche Czech Republic posted net and EBITDA margin of 0.936% and 3.84%, respectively in 2015 and Bayer Czech Republic generated margins of 2.89% and 3.93%.